Older patients with diffuse large B-cell lymphoma (DLBCL) are experiencing promising outcomes with the Pola-R-CHP therapy, challenging previous norms in oncology treatment.
Story Overview
- Pola-R-CHP therapy shows promising results in patients aged 80 and above.
- Real-world data reveals comparable response rates between older and younger patients.
- Adverse events are linked more to performance status than age.
- The study emphasizes the importance of dose management over age-based restrictions.
Real-World Data and Its Implications
The Gifu Hematology Study Group conducted a comprehensive retrospective study on 171 DLBCL patients, including those aged 80 and above, treated with Pola-R-CHP from August 2022 to May 2024 across Japan. This study found that the overall response rate (ORR) was similar between patients under 80 (97.8%) and those 80 or older (93.9%). Notably, Polatuzumab vedotin maintained higher dose intensity in older patients despite reductions in other chemotherapy agents like doxorubicin and cyclophosphamide.
These findings challenge the previous limitations of the POLARIX trial, which excluded patients over 80, and highlight the potential for Pola-R-CHP to be a viable first-line treatment for very elderly patients. Despite the promising response rates, the study did note a higher treatment-related mortality (TRM) in older patients (11.4% compared to 2.3% in younger patients), emphasizing the need for careful management of therapy-related risks.
Watch:
Understanding the Background
Diffuse large B-cell lymphoma is the most common aggressive form of non-Hodgkin lymphoma. The standard first-line treatment since the early 2000s has been R-CHOP. Polatuzumab vedotin, an innovative antibody-drug conjugate targeting CD79b, was approved following the POLARIX trial, which demonstrated improved progression-free survival in untreated DLBCL patients aged 18 to 80. The current study extends this knowledge by including patients over 80, a group traditionally overlooked in clinical trials.
The study’s real-world approach offers a significant contribution to geriatric oncology, where treatment options are often limited by age and associated comorbidities. By focusing on dose management rather than strict age limits, this study paves the way for more inclusive and effective cancer treatments.
Key Stakeholders in the Study
The study was conducted by the Gifu Hematology Study Group, involving seven institutions in Japan. Matthew Matasar from the Rutgers Cancer Institute has also played a significant role in comparing real-world data of Pola-R-CHP versus R-CHOP in older patients in the U.S. Pharmaceutical company Genentech/Roche, the developer of Polatuzumab vedotin, funded the POLARIX trial, which laid the groundwork for subsequent studies.
These stakeholders are motivated by the need to optimize treatment regimens for older cancer patients, balancing efficacy with safety. Their work is crucial in influencing treatment guidelines and informing policy decisions regarding the use of innovative therapies in geriatric oncology.
Future Directions and Considerations
Looking ahead, the focus will be on refining treatment strategies to reduce TRM while maintaining efficacy. This includes individualized dosing and nutritional assessments to better cater to the needs of patients aged 80 and above. The study’s findings support a shift towards Pola-R-CHP over R-CHOP in the fit elderly population, potentially delaying the need for subsequent treatments.
Continued research and real-world studies are necessary to further validate these findings and extend the benefits to broader patient populations. The ongoing dialogue between researchers, clinicians, and pharmaceutical companies will be vital in shaping the future of DLBCL treatment for very elderly patients.
Meet My Healthy Doc – instant answers, anytime, anywhere.
Sources:
ASH Conference
Targeted Oncology
PMC Article
ASCO Publications
Blood Advances
Taylor & Francis Online
EHA Congress
